Promosome v BioNTech (CFI, 10 March 2025)
| Date | 10 March 2025 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Local Division |
| Type of action | Application RoP262A |
| Registry reference | App_15/2025 · ORD_6596/2025 |
| Parties | BioNTech Innovative Manufacturing Services GmbH , Pfizer Manufacturing Belgium NV , Pfizer SAS, BioNTech Manufacturing GmbH , Pfizer AB , B… |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 10 March 2025 (UPC_CFI_846/2024, ACT_68533/2024, ORD_6596/2025), the judge-rapporteur of the Munich Local Division (A. Kupecz) largely granted the application of Promosome, claimant in an infringement action on EP 2 401 365 against five BioNTech group companies and four Pfizer group companies, for protection of a licence agreement and its amendment filed as exhibits. The order defines the circle of persons admitted to confidential information under Rule 262A.
Question
Which persons on the defendants’ side may access the confidential information, and should the Court order its return or destruction at the end of the proceedings?
Decision
The exhibits are treated as confidential, the defendants contesting neither the principle nor the scope of protection. Access may be restricted where the applicant’s grounds clearly outweigh the other party’s interest, with no more persons than necessary and at least one natural person per party together with its representatives (Rule 262A.5 and 6). Rule 262A.6 does not require the person admitted to be an employee or an Art. 48 representative, access extends to team members actively involved, lawyers, patent attorneys and support staff, under the representative’s personal responsibility. The confidentiality obligation survives the proceedings, and a penalty payment may sanction a culpable breach. The request for return or destruction is rejected for lack of legal basis and separate interest. So is the request concerning Court staff, to whom Rule 262A does not apply.
Key points for practice
- Practical point: counsel’s team actively involved in the case may see confidential exhibits without being named individually, but the representative is personally answerable for keeping them confidential.
Provisions applied
- Agreement on a Unified Patent Court
- Arts. 10, 45, 48 and 58
- Rules of Procedure
- Rules 102.2, 262.2, 262A and 333
- Case law cited
- Daedalus Prime v Xiaomi, Court of Appeal, 12 February 2025, Amazon v Nokia, Court of Appeal, 20 January 2025, Sanofi v Accord, Munich Local Division, 14 January 2025, Munich Local Division, 2 December 2024 (unpublished order)
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Confidentiality club.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantPfizer Manufacturing Belgium NV9 decisions in the corpusFollow this party
- claimantBioNTech Innovative Manufacturing Services GmbH5 decisions in the corpusFollow this party
- claimantBioNTech Manufacturing GmbH8 decisions in the corpusFollow this party
- claimantPfizer SAS7 decisions in the corpusFollow this party
- claimantPfizer AB7 decisions in the corpusFollow this party
- claimantB2 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application RoP262A
- Outcome (Dhenne Avocats summary)
- Le contrat de licence produit par Promosome est classé confidentiel. L'accès est limité aux représentants des défenderesses, à leurs équipes activement impliquées et à des personnes physiques désignées, sans obligation de restitution en fin d'instance.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 401 365mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- BioNTech Innovative Manufactur (CFI, 10 March 2025) cited in this record
- Daedalus Prime v Xiaomi Netherlands (CoA, 12 February 2025) cited in this record
- Amazon.com v Nokia (CoA, 20 January 2025) cited in this record
- Sanofi Mature IP v Accord Healthcare (CFI, 14 January 2025) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 401 365Reengineering mrna primary structure for enhanced protein production recorded proprietor: Scripps Research Institute | Mentioned in the analysis (role not qualified) Also mentioned in 6 other decision(s): Promosome v BioNTech (CFI, UPC_CFI_846/2024, 7 July 2026) · Promosome v BioNTech (CFI, 15 July 2025) · Promosome v BioNTech (CFI, 17 April 2025) · Promosome v BioNTech (CFI, 9 April 2025) · Promosome v BioNTech (CFI, 3 April 2025) · Promosome v BioNTech (CoA, 12 October 2026) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.